Asenapine vs Risperidone (Risperdal)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Asenapine

Marketed by AbbVie and partners

Approved in Schizophreniasmall molecule
Partial signal

NCT00212784 · Phase 3 · completed

This 52-week trial randomly assigned 1,225 people with schizophrenia to asenapine or to olanzapine, with participants, carers, investigators and outcome assessors all unaware of assignment. The primary measure was change in total PANSS symptom score. Asenapine improved symptoms by 21.0 points against 27.5 points for olanzapine, a difference favouring olanzapine at p<0.0001, so asenapine was less effective than its active comparator on this measure.

Reported efficacy

Change in total PANSS score at endpoint (Screening, Week 76, 100, and once every 24 weeks thereafter until endpoint): Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint (unclear)

Result source: NCT00212771

Risperidone (Risperdal)

Marketed by Johnson & Johnson

Approved in Schizophreniasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: September 2027 · NCT04478838 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAsenapineRisperidone (Risperdal)
PANSS total, change-25.5 vs -17.8−7.7 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
18 other results
  • -21.7 vs -16.2 5 mg BID · wk 6 · n 111 · Phase 3 · primary NCT01617187
  • -12.2 vs -0.9 5 mg BID · wk 6 · n 173 · Phase 3 · primary NCT01098110
  • -14.2 vs -0.9 10 mg BID · wk 6 · n 178 · Phase 3 · primary NCT01098110
  • -23.7 vs -17.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · primary NCT01190254
  • -17.4 vs -16.2 2.5 mg BID · wk 6 · n 96 · Phase 3 · primary NCT01617187
  • -19 vs -15.4 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -17.1 vs -15.5 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -14.8 vs -13.2 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -12.5 vs -10.7 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -9.1 vs -7.1 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -4.9 vs -4.8 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -17 vs -15.4 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -12.3 vs -15.5 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -12 vs -13.2 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -9.9 vs -10.7 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -7.2 vs -7.1 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -4 vs -4.8 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
  • -21 vs -27.5 wk 52 · Phase 3 · primary NCT00212784
-16.5 vs -9.2−7.2 vs placebo120 mg · wk 8 · n 114NCT02109562
1 other result
  • -15.4 vs -9.2 90 mg · wk 8 · n 111 · Phase 3 · primary NCT02109562
CGI-S, change-1.3 vs -0.8−0.5 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
17 other results
  • -1.2 vs -1 5 mg BID · wk 6 · n 111 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.2 5 mg BID · wk 6 · n 173 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.7 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -0.2 vs -0.2 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.2 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · secondary NCT01190254
  • -0.9 vs -1 2.5 mg BID · wk 6 · n 96 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.8 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.7 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -0.1 vs -0.2 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
-0.9 vs -0.5−0.4 vs placebo120 mg · wk 8 · n 114NCT02109562
1 other result
  • -0.9 vs -0.5 90 mg · wk 8 · n 111 · Phase 3 · secondary NCT02109562
PANSS response39.3% vs 20.7%+18.6 vs placebo5 mg BID · wk 6 · n 173NCT01098110
1 other result
  • 43.8% vs 20.7% 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
—Not posted · NCT00297388
PSP, change—Not posted · NCT00212771—Not posted · NCT00297388
Relapse (% of patients)—Not posted · NCT00212771—Not posted · NCT00297388

PANSS total, change

Asenapine
-25.5 vs -17.8−7.7 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
18 other results
  • -21.7 vs -16.2 5 mg BID · wk 6 · n 111 · Phase 3 · primary NCT01617187
  • -12.2 vs -0.9 5 mg BID · wk 6 · n 173 · Phase 3 · primary NCT01098110
  • -14.2 vs -0.9 10 mg BID · wk 6 · n 178 · Phase 3 · primary NCT01098110
  • -23.7 vs -17.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · primary NCT01190254
  • -17.4 vs -16.2 2.5 mg BID · wk 6 · n 96 · Phase 3 · primary NCT01617187
  • -19 vs -15.4 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -17.1 vs -15.5 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -14.8 vs -13.2 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -12.5 vs -10.7 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -9.1 vs -7.1 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -4.9 vs -4.8 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -17 vs -15.4 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -12.3 vs -15.5 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -12 vs -13.2 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -9.9 vs -10.7 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -7.2 vs -7.1 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -4 vs -4.8 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
  • -21 vs -27.5 wk 52 · Phase 3 · primary NCT00212784
Risperidone (Risperdal)
-16.5 vs -9.2−7.2 vs placebo120 mg · wk 8 · n 114NCT02109562
1 other result
  • -15.4 vs -9.2 90 mg · wk 8 · n 111 · Phase 3 · primary NCT02109562

CGI-S, change

Asenapine
-1.3 vs -0.8−0.5 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
17 other results
  • -1.2 vs -1 5 mg BID · wk 6 · n 111 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.2 5 mg BID · wk 6 · n 173 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.7 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -0.2 vs -0.2 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.2 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · secondary NCT01190254
  • -0.9 vs -1 2.5 mg BID · wk 6 · n 96 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.8 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.7 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -0.1 vs -0.2 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
Risperidone (Risperdal)
-0.9 vs -0.5−0.4 vs placebo120 mg · wk 8 · n 114NCT02109562
1 other result
  • -0.9 vs -0.5 90 mg · wk 8 · n 111 · Phase 3 · secondary NCT02109562

PANSS response

Asenapine
39.3% vs 20.7%+18.6 vs placebo5 mg BID · wk 6 · n 173NCT01098110
1 other result
  • 43.8% vs 20.7% 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
Risperidone (Risperdal)
—Not posted · NCT00297388

PSP, change

Asenapine
—Not posted · NCT00212771
Risperidone (Risperdal)
—Not posted · NCT00297388

Relapse (% of patients)

Asenapine
—Not posted · NCT00212771
Risperidone (Risperdal)
—Not posted · NCT00297388
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Asenapine: 5 of 5 rows · Risperidone (Risperdal): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAsenapine
Rows use multiple source trials
Risperidone (Risperdal)
Rows use multiple source trials
PANSS Total
absolute change · score
No placebo or comparator arm
-11.08 score @ 52wka,b,c,d
NCT01244828 · Phase 3 · registry result, not featured evidence
show 1 more dose
-5.48 score
NCT01244828 · Phase 3 · registry result, not featured evidence
28.1 score @ 26wkb,c,d
NCT01855074 · Phase 4 · registry result, not featured evidence
Dropout rate
44.4%5 mg twice dailye
NCT01549041 · Phase 4 · registry result, not featured evidence
show 23 more results
16.7%10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
54.8%5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence
0%5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
1%2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
49.7%
NCT01244828 · Phase 3 · registry result, not featured evidence
35.2%5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
40.1%10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
50%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
20.9%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
20.8%5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
17.3%2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
33.7%
NCT00174265 · Phase 3 · registry result, not featured evidence
50.4%
NCT00145496 · Phase 3 · registry result, not featured evidence
30.4%
NCT00150176 · Phase 3 · registry result, not featured evidence
15.7%
NCT00265343 · Phase 3 · registry result, not featured evidence
67.7%
NCT00156065 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
33.3%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
25%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
78.3%180 mg subcutaneouse
NCT03978832 · Phase 4 · registry result, not featured evidence
show 22 more results
5.9%CT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
0%CT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
14.3%HBT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
5.9%HBT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
0%
NCT01050582 · Phase 4 · registry result, not featured evidence
17.5%
NCT01855074 · Phase 4 · registry result, not featured evidence
29.6%
NCT00299702 · Phase 4 · registry result, not featured evidence
0%PALI ER Delayed Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
0%PALI ER Immediate Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
16.7%
NCT00056498 · Phase 4 · registry result, not featured evidence
28.6%120 mg
NCT02109562 · Phase 3 · registry result, not featured evidence
22.4%90 mg
NCT02109562 · Phase 3 · registry result, not featured evidence
—4 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
25%4 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
—2 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
40%120 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
6.7%90 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
6.7%60 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
29.4%DLP-114 Alpha-4 (6-months)
NCT04418466 · Phase 1/2 · registry result, not featured evidence
35.3%DLP-114 Alpha-7 (12-months)
NCT04418466 · Phase 1/2 · registry result, not featured evidence
44%
NCT01786239 · Phase na · registry result, not featured evidence
Discontinued due to AEs
22.2%5 mg twice dailye
NCT01549041 · Phase 4 · registry result, not featured evidence
show 23 more results
0%10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
22.3%5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence
0%5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
0%2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
23.6%
NCT01244828 · Phase 3 · registry result, not featured evidence
17%5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
17.6%10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
0%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
5.1%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
7.5%5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
6.1%2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
8.1%
NCT00174265 · Phase 3 · registry result, not featured evidence
17.2%
NCT00145496 · Phase 3 · registry result, not featured evidence
8.2%
NCT00150176 · Phase 3 · registry result, not featured evidence
7.5%
NCT00265343 · Phase 3 · registry result, not featured evidence
11.8%
NCT00156065 · Phase 3 · registry result, not featured evidence
—5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
1.4%180 mg subcutaneouse
NCT03978832 · Phase 4 · registry result, not featured evidence
show 22 more results
—CT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
—CT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
—HBT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
—HBT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
—
NCT01050582 · Phase 4 · registry result, not featured evidence
1.3%
NCT01855074 · Phase 4 · registry result, not featured evidence
0%
NCT00299702 · Phase 4 · registry result, not featured evidence
—PALI ER Delayed Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
—PALI ER Immediate Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
—
NCT00056498 · Phase 4 · registry result, not featured evidence
1.7%120 mg
NCT02109562 · Phase 3 · registry result, not featured evidence
0%90 mg
NCT02109562 · Phase 3 · registry result, not featured evidence
—4 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
0%4 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
—2 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
—120 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
—90 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
—DLP-114 Alpha-4 (6-months)
NCT04418466 · Phase 1/2 · registry result, not featured evidence
—DLP-114 Alpha-7 (12-months)
NCT04418466 · Phase 1/2 · registry result, not featured evidence
—
NCT01786239 · Phase na · registry result, not featured evidence
Serious AEs
0%5 mg twice dailye
NCT01549041 · Phase 4 · registry result, not featured evidence
show 23 more results
0%10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
20.4%5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence
4.4%5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.2%2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
8.9%
NCT01244828 · Phase 3 · registry result, not featured evidence
5.7%5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
2.8%10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
12.5%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
3.6%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
2.8%5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
3.1%2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
4.7%
NCT00174265 · Phase 3 · registry result, not featured evidence
12.3%
NCT00145496 · Phase 3 · registry result, not featured evidence
3.1%
NCT00150176 · Phase 3 · registry result, not featured evidence
6.7%
NCT00265343 · Phase 3 · registry result, not featured evidence
14.1%
NCT00156065 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
4.3%180 mg subcutaneouse
NCT03978832 · Phase 4 · registry result, not featured evidence
show 22 more results
18.8%CT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
8.3%CT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
8.3%HBT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
0%HBT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
0%
NCT01050582 · Phase 4 · registry result, not featured evidence
1.3%
NCT01855074 · Phase 4 · registry result, not featured evidence
17.3%
NCT00299702 · Phase 4 · registry result, not featured evidence
4%PALI ER Delayed Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
3.1%PALI ER Immediate Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
3.3%
NCT00056498 · Phase 4 · registry result, not featured evidence
0.9%120 mg
NCT02109562 · Phase 3 · registry result, not featured evidence
0%90 mg
NCT02109562 · Phase 3 · registry result, not featured evidence
0%4 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
—4 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
—2 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
6.7%120 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
0%90 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
0%60 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
0%DLP-114 Alpha-4 (6-months)
NCT04418466 · Phase 1/2 · registry result, not featured evidence
7.1%DLP-114 Alpha-7 (12-months)
NCT04418466 · Phase 1/2 · registry result, not featured evidence
0%
NCT01786239 · Phase na · registry result, not featured evidence
Most frequent reported AEs
5 mg twice dailye
daytime drowsiness 22.2%
NCT01549041 · Phase 4 · registry result, not featured evidence
show 19 more results
10 mg daily in the evening
daytime drowsiness 0%
NCT01549041 · Phase 4 · registry result, not featured evidence
5/10 mg BID
nasopharyngitis 21.7%
schizophrenia 10.8%
somnolence 10.8%
NCT01142596 · Phase 3 · registry result, not featured evidence
5 mg BID
insomnia 15% (placebo 13.9%)
headache 8.8% (placebo 2%)
anxiety 7.1% (placebo 11.9%)
NCT01617187 · Phase 3 · registry result, not featured evidence
2.5 mg BID
headache 10.3% (placebo 2%)
insomnia 9.3% (placebo 13.9%)
anxiety 7.2% (placebo 11.9%)
NCT01617187 · Phase 3 · registry result, not featured evidence
nasopharyngitis 21%
somnolence 12.7%
weight increased 12.7%
NCT01244828 · Phase 3 · registry result, not featured evidence
5 mg BID
akathisia 11.4% (placebo 5.2%)
hypoaesthesia oral 10.9% (placebo 3.4%)
insomnia 9.7% (placebo 12.1%)
NCT01098110 · Phase 3 · registry result, not featured evidence
10 mg BID
schizophrenia 13.8% (placebo 24.1%)
somnolence 12.2% (placebo 1.7%)
akathisia 10.5% (placebo 5.2%)
NCT01098110 · Phase 3 · registry result, not featured evidence
accidental overdose 12.5%
acne 12.5%
akathisia 12.5%
NCT01190267 · Phase 3 · registry result, not featured evidence
somnolence 14.8%
headache 6.6%
sedation 5.1%
NCT01190267 · Phase 3 · registry result, not featured evidence
5.0 mg BID
somnolence 17% (placebo 6.9%)
sedation 11.3% (placebo 2%)
insomnia 9.4% (placebo 5.9%)
NCT01190254 · Phase 3 · registry result, not featured evidence
2.5 mg BID
somnolence 20.4% (placebo 6.9%)
dizziness 7.1% (placebo 1%)
headache 7.1% (placebo 5.9%)
NCT01190254 · Phase 3 · registry result, not featured evidence
insomnia 10.6%
weight increased 5.9%
headache 2.4%
NCT00174265 · Phase 3 · registry result, not featured evidence
insomnia 17.6%
somnolence 14.8%
headache 13.5%
NCT00145496 · Phase 3 · registry result, not featured evidence
insomnia 20.1% (placebo 24.5%)
somnolence 16% (placebo 17.2%)
weight increased 14.4% (placebo 10.9%)
NCT00150176 · Phase 3 · registry result, not featured evidence
headache 5.2%
influenza 5.2%
schizophrenia 5.2%
NCT00265343 · Phase 3 · registry result, not featured evidence
insomnia 18.5%
headache 10.9%
parkinsonism 10.9%
NCT00156065 · Phase 3 · registry result, not featured evidence
5 mg
dystonia 66.7%
dizziness 33.3%
nausea 33.3%
NCT01206517 · Phase 1 · registry result, not featured evidence
10 mg
hypoaesthesia oral 50%
dizziness 38.9%
dysgeusia 38.9%
NCT01206517 · Phase 1 · registry result, not featured evidence
2.5 mg
sedation 33.3%
dysgeusia 16.7%
hypoaesthesia oral 16.7%
NCT01206517 · Phase 1 · registry result, not featured evidence
180 mg subcutaneouse
upper respiratory tract infection 13%
blood prolactin increased 8.7%
decreased appetite 8.7%
NCT03978832 · Phase 4 · registry result, not featured evidence
show 18 more results
bmi increase normal/overweight to obese 31.3%
ldl or triglyceride increase 25%
prolactin related symptom 12.5%
NCT00333177 · Phase 4 · registry result, not featured evidence
bmi increase normal/overweight to obese 25%
prolactin related symptom 16.7%
ldl or triglyceride increase 8.3%
NCT00333177 · Phase 4 · registry result, not featured evidence
ldl or triglyceride increase 41.7%
prolactin related symptom 16.7%
bmi increase normal/overweight to obese 0%
NCT00333177 · Phase 4 · registry result, not featured evidence
bmi increase normal/overweight to obese 12.5%
ldl or triglyceride increase 6.3%
prolactin related symptom 6.3%
NCT00333177 · Phase 4 · registry result, not featured evidence
blood prolactin increased 0.8%
drug ineffective 0.8%
eye infection 0.8%
NCT01050582 · Phase 4 · registry result, not featured evidence
extrapyramidal disorder 1.3%
NCT01855074 · Phase 4 · registry result, not featured evidence
insomnia 26.3%
tremor 21.8%
anxiety 17.9%
NCT00299702 · Phase 4 · registry result, not featured evidence
constipation 9.1%
insomnia 9.1%
somnolence 8.1%
NCT00535132 · Phase 4 · registry result, not featured evidence
insomnia 9.2%
headache 8.2%
constipation 6.1%
NCT00535132 · Phase 4 · registry result, not featured evidence
120 mg
injection site pain 22.2% (placebo 19.5%)
headache 15.4% (placebo 23.7%)
weight increased 12.8% (placebo 3.4%)
NCT02109562 · Phase 3 · registry result, not featured evidence
90 mg
headache 17.4% (placebo 23.7%)
injection site pain 15.7% (placebo 19.5%)
weight increased 13% (placebo 3.4%)
NCT02109562 · Phase 3 · registry result, not featured evidence
4 mg
akathisia 25%
diarrhoea 25%
abdominal discomfort 0%
NCT04567524 · Phase 2 · registry result, not featured evidence
2 mg
alanine aminotransferase increased 25%
weight increased 25%
abdominal discomfort 0%
NCT04567524 · Phase 2 · registry result, not featured evidence
120 mg
cough 20%
dyspepsia 20%
weight increased 20%
NCT01677377 · Phase 2 · registry result, not featured evidence
90 mg
weight increased 33.3%
headache 20%
dyspepsia 13.3%
NCT01677377 · Phase 2 · registry result, not featured evidence
60 mg
weight increased 26.7%
headache 20%
rash 20%
NCT01677377 · Phase 2 · registry result, not featured evidence
arthralgia 21.4%
weight increased 21.4%
abdominal pain 14.3%
NCT04418466 · Phase 1/2 · registry result, not featured evidence
insomnia 21.4%
implant site pain 14.3%
injection site discomfort 14.3%
NCT04418466 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 4 versus Phase 3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Asenapine

BPRS Total 7.72 score @ 2wk5 mg twice daily
absolute change · score
No placebo or comparator arm
NCT01549041 · Phase 4 · registry result, not featured evidence
show 1 more result
16.08 score @ 2wk10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
Time to Loss of Efficacy 5.82 months5/10 mg BID
time to event · months
Extension (open-label)
No placebo or comparator arm
NCT01142596 · Phase 3 · registry result, not featured evidence · converted to months from 177 days as posted
show 1 more result
12.09 months*5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence · converted to months from 368 days as posted
PANSS 30% 25.2% (n=111) vs 19.2% (n=99) placebo @ 6wk5 mg BID
responder rate · % of participants
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
0% (n=111) vs 2.1% (n=99) placebo @ 0.57wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.4% (n=111) vs 5.1% (n=99) placebo @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.4% (n=111) vs 7.1% (n=99) placebo @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
14.4% (n=111) vs 13.1% (n=99) placebo @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
16.2% (n=111) vs 14.1% (n=99) placebo @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
21.6% (n=111) vs 17.2% (n=99) placebo @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
49% (n=104) vs 36% (n=100) placebo @ 8wk*5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence · converted to % from 51 participants as posted
72.1% (n=104) vs 62% (n=100) placebo @ 8.4wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
14.6% (n=96) vs 19.2% (n=99) placebo @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
0% (n=96) vs 2.1% (n=99) placebo @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
2.1% (n=96) vs 5.1% (n=99) placebo @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.2% (n=96) vs 7.1% (n=99) placebo @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
8.3% (n=96) vs 13.1% (n=99) placebo @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
10.4% (n=96) vs 14.1% (n=99) placebo @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
15.6% (n=96) vs 17.2% (n=99) placebo @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
50% (n=96) vs 36% (n=100) placebo @ 8wk*2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence · converted to % from 48 participants as posted
64.2% (n=96) vs 62% (n=100) placebo @ 8.4wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
Weight 1.3 vs 0.3 placebo kg @ 6wk5 mg BID
absolute change · kg
NCT01617187 · Phase 3 · registry result, not featured evidence
show 2 more results
1.3 vs 0.3 placebo kg @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
0 vs 2.6 Olanzapine kg @ 26wk
NCT00145496 · Phase 3 · registry result, not featured evidence
CGI-I 33.3% (n=111) vs 37.8% (n=99) placebo @ 0.57wk5 mg BID
responder rate · % of participants
NCT01617187 · Phase 3 · registry result, not featured evidence
show 19 more results
46.8% (n=111) vs 45.5% (n=99) placebo @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
60.4% (n=111) vs 54.5% (n=99) placebo @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
63.1% (n=111) vs 58.6% (n=99) placebo @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
62.2% (n=111) vs 60.6% (n=99) placebo @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
64% (n=111) vs 64.6% (n=99) placebo @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
66.7% (n=111) vs 62.6% (n=99) placebo @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
63.6% (n=173) vs 41.4% (n=174) placebo @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
39.4% (n=104) vs 28% (n=100) placebo @ 8wk*5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence · converted to % from 41 participants as posted
60.1% (n=104) vs 54.7% (n=100) placebo @ 8.3wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
70.2% (n=178) vs 41.4% (n=174) placebo @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
34.7% (n=96) vs 37.8% (n=99) placebo @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
51% (n=96) vs 45.5% (n=99) placebo @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
51% (n=96) vs 54.5% (n=99) placebo @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
54.2% (n=96) vs 58.6% (n=99) placebo @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
58.3% (n=96) vs 60.6% (n=99) placebo @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
60.4% (n=96) vs 64.6% (n=99) placebo @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
59.4% (n=96) vs 62.6% (n=99) placebo @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
37.5% (n=96) vs 28% (n=100) placebo @ 8wk*2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence · converted to % from 36 participants as posted
47.1% (n=96) vs 54.7% (n=100) placebo @ 8.3wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Negative -0.5 vs -0.8 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 15 more results
-1.3 vs -1.1 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -1.8 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.3 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.1 vs -3 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.4 vs -2.6 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.3 vs -3.2 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.72 vs -0.24 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-3.27 vs -0.24 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-0.7 vs -0.8 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.2 vs -1.1 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.6 vs -1.8 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -2.3 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -3 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.3 vs -2.6 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.3 vs -3.2 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
PANSS Positive -1.6 vs -1.7 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 15 more results
-2.8 vs -2.6 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.9 vs -3.7 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5 vs -4.5 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.7 vs -5 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.3 vs -5.5 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.2 vs -5.4 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.31 vs -0.85 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-4.63 vs -0.85 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-1.2 vs -1.7 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -2.6 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.4 vs -3.7 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4 vs -4.5 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.1 vs -5 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.2 vs -5.5 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.6 vs -5.4 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
PANSS General Psychopathology -2.7 vs -2.4 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-4.9 vs -3.6 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.2 vs -5.4 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.4 vs -6.7 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-8.2 vs -7.7 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-9.2 vs -7.6 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-10.1 vs -8 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.26 vs 0.19 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-11.5 vs -8.5 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-6.34 vs 0.19 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-2.2 vs -2.4 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.8 vs -3.6 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.1 vs -5.4 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.9 vs -6.7 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.9 vs -7.7 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-8.8 vs -7.6 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-8.9 vs -8 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-10.9 vs -8.5 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Marder Positive -1.8 vs -2 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-2.9 vs -2.8 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4 vs -4.1 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.4 vs -5.1 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.3 vs -5.6 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.7 vs -6.1 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.6 vs -6.2 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.78 vs -1.37 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-8.9 vs -6.1 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-5.03 vs -1.37 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-1.3 vs -2 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.8 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.9 vs -4.1 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.5 vs -5.1 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.8 vs -5.6 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.1 vs -6.1 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.8 vs -6.2 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.9 vs -6.1 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Marder Negative -0.8 vs -0.7 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-1.9 vs -1.3 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.8 vs -2 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.2 vs -2.5 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.8 vs -3.5 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.9 vs -3 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.7 vs -4 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.77 vs -0.41 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-5.3 vs -3.7 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-3.35 vs -0.41 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-1.2 vs -0.7 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.7 vs -1.3 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2 vs -2 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.6 vs -2.5 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.9 vs -3.5 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.5 vs -3 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.4 vs -4 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.2 vs -3.7 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Marder Disorganized Thought -0.7 vs -0.7 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-1.4 vs -0.7 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2 vs -1.5 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.1 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.1 vs -2.4 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.5 vs -2.4 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.3 vs -2.7 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.48 vs 0.24 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-4.8 vs -3.4 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-2.85 vs 0.24 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-0.3 vs -0.7 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1 vs -0.7 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.3 vs -1.5 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -2.1 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.4 vs -2.4 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.5 vs -2.4 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.8 vs -2.7 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.3 vs -3.4 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Marder Uncontrolled Hostility/Excitement -0.3 vs -0.5 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-0.5 vs -0.7 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.8 vs -0.9 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.9 vs -1 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.8 vs -1 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.5 vs -1.4 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.8 vs -1.1 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.77 vs 0.86 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-3.8 vs -2.8 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-1.4 vs 0.86 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-0.4 vs -0.5 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.5 vs -0.7 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.9 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.8 vs -1 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.5 vs -1 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.4 vs -1.4 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.1 vs -1.1 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.8 vs -2.8 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence

+ 31 further endpoints in the CSV export.

Risperidone (Risperdal)

PANSS Total -0.2 score @ 0wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 1 Day 2
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total 0.9 score @ 1wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 1 Day 8
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total 0.7 score @ 2wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 1 Day 15
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -0.4 score @ 3wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 1 Day 22
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -0.9 score @ 4wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 2 Day 29
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -0.5 score @ 7wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 2 Day 50
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -2.9 score @ 8wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 3 Day 57
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -0.9 score @ 12wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 4 Day 85
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total 1.6 score @ 16wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Day 113-EOS
NCT03978832 · Phase 4 · registry result, not featured evidence
CGI-S -0.1 score @ 0wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Change from baseline: Dose 1/Day 2
NCT03978832 · Phase 4 · registry result, not featured evidence
CGI-S 0 score @ 1wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Change from baseline: Dose 1/Day 8
NCT03978832 · Phase 4 · registry result, not featured evidence
CGI-S 0 score @ 2wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Change from baseline: Dose 1/Day 15
NCT03978832 · Phase 4 · registry result, not featured evidence

+ 21 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asenapine's landscape · Risperidone (Risperdal)'s landscape